By reprogramming a 7–year–old girl’s own immune cells to attack an aggressive form of childhood leukemia, a pediatric oncologist has achieved a complete response in his patient, who faced grim prospects when she relapsed after conventional treatment. The innovative experimental therapy used bioengineered T cells, custom–designed to multiply rapidly in the patient, and then destroy leukemia cells. After the treatment, the child’s doctors found that she had no evidence of cancer.
To view Multimedia News Release, go to http://www.multivu.com/mnr/50777-chop-engineered-immune-t-cell-therapy-anticancer-effect-in-children
A first-of-a-kind neural stem cell therapy that works with a common cold virus to seek out and attack a lethal and aggressive brain cancer is being tested at Northwestern Medicine in a Phase I clinical trial for patients newly diagnosed with malignant glioma.
The novel drug to treat malignant glioma, notorious for recurring after typical bouts of standard cancer treatment, was developed by a Northwestern scientist and has been approved as an investigational drug by the U.S. Food and Drug Administration. This is only the second time the University has supported and filed an investigational new drug as a sponsor.
To view the multimedia release go to:
https://www.multivu.com/players/English/7944251-northwestern-medicine-stem-cell-trial/
New data revealed that nearly 100 percent (99%) of 200 U.S. primary care physicians surveyed agree that heart disease and stroke are the number one cause of death and disability among type 2 diabetes patients; however, almost 40 percent (36%) of these physicians underestimate the number of patients who die from cardiovascular disease. Furthermore, while people with diabetes are two to four times more likely to have heart disease than people without diabetes, the survey, conducted by Harris Interactive and supported by Merck, found only one out of five (21%) patients (n=664) listed heart attack or heart failure as their biggest worry regarding diabetes complications, and even fewer patients (7%) listed stroke.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/merck/50638/
Death Be Not Proud is the thrilling second installment in The Secret of the Journal series. Professor Emma D’Eresby flees her teaching position in Maine after a vicious attack by a psychotic colleague, but mysterious secrets and suspense still follow her back to her hometown in England. Learn more about this book here, http://bit.ly/1aLIAPr Romantic Thriller
It was too late. Andor Katona, an ancient immortal warrior, had fought his last battle, just as his lifemate arrived to save him. As he lies dying he realizes she is surrounded by danger and hopes his brothers will arrive in time to save her.
Lorraine Peters has seen enough of death. And she’s willing to fight death to have him. With wits, courage and new friends to help her she might survive this attack and those that are coming. But, even if Andor survives, the fight is far from over.
From #1 New York Times bestselling author Christine Feehan. Find our more at https//www.christinefeehan.com Romance, horror, paranormal
It was too late. Andor Katona, an ancient immortal warrior, had fought his last battle, just as his lifemate arrived to save him. As he lies dying he realizes she is surrounded by danger and hopes his brothers will arrive in time to save her.
Lorraine Peters has seen enough of death. And she’s willing to fight death to have him. With wits, courage and new friends to help her she might survive this attack and those that are coming. But, even if Andor survives, the fight is far from over.
From #1 New York Times bestselling author Christine Feehan. Find our more at https//www.christinefeehan.com Romance, horror, paranormal
Global biotherapeutics leader CSL Behring today announced that results were published in the New England Journal of Medicine (NEJM) from the COMPACT study, a pivotal Phase III study evaluating the safety and efficacy of CSL830 (a novel, investigational, self-administered, subcutaneous C1-Esterase Inhibitor [C1-INH] Human replacement therapy) for the prevention of HAE attacks. The study met its primary efficacy endpoint, significantly reducing the time-normalized number of HAE attacks. In addition, the study met its secondary endpoints, including the responder rate (patients who had at least a 50% reduction in their attack rate) and the number of rescue medication uses. If approved by the FDA, CSL830 would be the first and only subcutaneous preventative therapy for HAE.
To view the multimedia release go to:
https://www.multivu.com/players/English/8056151-csl-behring-subcutaneous-c1-esterase-inhibitor-hae-patients/
